Moreover, the gene expression signatures acquired after treatment with different BETi also highly overlapped in different lymphoma models, for instance, downregulation of E2F target, MYC target, and inhibition of the NF-κB, JAK/STAT, PI3K/AKT, MAPK signaling pathways have been most frequently reported [21, 72, 74, 75, 79, 80, 82–85]. This evidence concerns the gene MYC and lymphoma.